This study describes a methodology for generating stable, cloned, EBV-transformed IgG-and IgM-producing human B cell lines. Using these lines we have characterized immunoglobulin V gene utilization in an anti-DNA-associated idiotypic system. The 31 anti-DNA-associated idiotype is encoded preferentially by the VKl gene family, and, in all probability, reflects a germ line gene-encoded framework determinant. Analysis of these lines indicates that the DNA-binding antibodies produced by B cell lines from SLE patients may differ from DNA binding myeloma proteins and from natural autoantibodies. (J. Clin. Invest. 1991. 87:1519-1525.) Key words: clonal EBV lines * anti-DNA idiotype * systemic lupus erythematosus * autoantibody Introduction Little is known about the etiology of autoantibody production in systemic lupus erythematosus (SLE),I and animal models of the disease have led to disparate views. Many ofthe manipulations performed in studies of lupus-prone mice clearly cannot be undertaken in studies ofthe human disease; nonetheless, the study of the autoantibodies themselves can be very revealing. Serologic studies of SLE have employed idiotypic analyses to identify and characterize subsets of autoantibodies that bind DNA and structurally related antibodies that do not bind DNA. One approach has been to generate antiidiotypic reagents to monoclonal anti-DNA antibodies. However, it is not clear how closely the selected monoclonal autoantibodies mirror the pathogenic anti-DNA antibodies in disease. The approach favored by our laboratory has been to generate antiidiotypes to the heterogenous anti-DNA antibodies present in the serum and kidneys of individuals with SLE. The 3I antiidiotype recognizes a determinant on kappa light chains of anti-DNA antibodies (1). High titered expression of31-reactive antibodies is present in -80% of SLE patients with anti-DNA activity. We studied expression of the 31 idiotype in the serum ofrelatives ofSLE patients, as well as on monoclonal immunoglobulins in the serum of individuals with monoclonal gammopathies (1, 2) to obtain structural and genetic information
Introduction
Little is known about the etiology of autoantibody production in systemic lupus erythematosus (SLE),I and animal models of the disease have led to disparate views. Many ofthe manipulations performed in studies of lupus-prone mice clearly cannot be undertaken in studies ofthe human disease; nonetheless, the study of the autoantibodies themselves can be very revealing. Serologic studies of SLE have employed idiotypic analyses to identify and characterize subsets of autoantibodies that bind DNA and structurally related antibodies that do not bind DNA. One approach has been to generate antiidiotypic reagents to monoclonal anti-DNA antibodies. However, it is not clear how closely the selected monoclonal autoantibodies mirror the pathogenic anti-DNA antibodies in disease. The approach favored by our laboratory has been to generate antiidiotypes to the heterogenous anti-DNA antibodies present in the serum and kidneys of individuals with SLE. The 3I antiidiotype recognizes a determinant on kappa light chains of anti-DNA antibodies (1) . High titered expression of31-reactive antibodies is present in -80% of SLE patients with anti-DNA activity. We studied expression of the 31 idiotype in the serum ofrelatives ofSLE patients, as well as on monoclonal immunoglobulins in the serum of individuals with monoclonal gammopathies (1, 2) to obtain structural and genetic information about 31-reactive antibodies. These analyses suggested two provocative hypotheses: (a) autoantibodies and protective antibodies are structurally and probably genetically related; and (b) malignant B cells express an immunoglobulin repertoire skewed towards autoreactivity. The study ofmyeloma proteins also suggested that the 31 idiotype represents a germ line-encoded determinant on kappa light chains because 31 reactivity is common to both IgM and IgG antibodies. In contrast, a second antiidiotype, F4, recognizes a determinant on the heavy chain variable region of anti-DNA antibodies in -60% of patients with SLE with anti-DNA activity. ELISA and Western blot analyses of SLE sera and of myeloma proteins show F4 reactivity to be almost exclusively limited to cationic IgG antibodies and to be highly associated with DNA binding activity (3) . Because F4 reactivity is present much more commonly on IgG than on IgM antibodies, the F4 antiidiotype may recognize a somatically generated determinant, the appearance of which is coincident with heavy chain class switching.
Although many studies of autoantibodies have focused on myeloma proteins, the monoclonal autoantibodies produced by malignant B cells may differ from the autoantibodies of autoimmune diseases. For this reason, it is crucial to pursue the analysis ofpathogenic autoantibodies produced by B cells from autoimmune individuals. We now report the production of monoclonal EBV-transformed B cell lines from three individuals with SLE as well as from one with multiple myeloma whose myeloma protein expresses both the 31 and F4 idiotypes. We have generated IgM-, G-, and A-producing cell lines expressing the 31 idiotype and IgG-producing cell lines expressing the F4 idiotype. These cell lines were cloned; their immunoglobulin products were characterized to define antigenic specificity and RNA analyzed to determine variable region gene family utilization. We describe a protocol for generating cloned EBV-transformed lines and we demonstrate that SLE B cell lines differ from idiotypically related myeloma proteins; these differences may provide clues to the etiology of SLE.
Methods
Production and cloning ofEB V-transformed cell lines. All SLE patients met revised ARA criteria for disease. Peripheral blood lymphocytes were obtained from two individuals with SLE. Blood was drawn at a time when the serum displayed elevated titers ofidiotype reactive antibodies as tested by radioimmunoassay. Spleen cells were harvested from another individual with SLE who underwent splenectomy. Bone marrow was obtained from one patient with multiple myeloma whose myeloma protein is 31-and F4-reactive. Mononuclear cells were isolated by centrifugation on Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, NJ), and plated at 1 x 106 cells/ml in 24-well tissue culture plates in RPMI (Gibco, Grand Island, NY) supplemented with 10% FCS (Hyclone Laboratories, Inc., Logan, UT), 1% penicillin/streptomycin, 1% glutamine, 1% sodium pyruvate (Hazelton Biologics, Lenexa, KS), 1% nonessential amino acids (Gibco), and 0.01 mM Hepes 8) (American Type Culture Collection, Rockville, MD), and 50 ng of cyclosporine A was added. Transformants grew in every well. Each well was tested for idiotypic reactivity, i.e., for the presence of 3I-or F4-reactive immunoglobulin by ELISA. Antibodies were shown to be devoid of rheumatoid factor activity based on their inability to react with an isotype-and allotype-matched irrelevant IgGI antibody in the ELISA assay (data not shown). Cloning of cells was performed within 4 wk of transformation. Cells were plated at 3, 10, 30, and 100 cells/well in 96-well round-bottomed microtiter wells in medium supplemented with 10% FCS and 20% J774 conditioned medium. The mouse macrophage line J774 derives from a reticulum cell sarcoma and has been shown to produce a variety of macrophage specific factors (4, 5) . The line was grown in DME medium with 10% FCS. Supernatant from a 48-h dense culture was harvested and filtered before use. Plates in which cells grew in more than one of every three wells were discarded. Presumed clones were grown to mass culture in RPMI medium supplemented as above but without the addition of J774 cell conditioned medium. For isotype, idiotype, and DNA binding assays described below, cells were grown in serum free medium.
Assayfor isotype. The isotype of secreted immunoglobulin was determined by ELISA. Goat anti-human immunoglobulin M, G, and A (Sigma Chemical Co., St. Louis, MO) was adsorbed to microtiter wells (Costar 35, Cambridge, MA) at 10 Mg/ml. Wells were blocked with PBS/3% BSA/5% FCS. Supernatant (100 Ml/well) was added for 60 min at 370C. Wells were washed with PBS-0.05% Tween and then incubated separately with peroxidase labeled goat anti-human IgM, IgG, or IgA (Sigma Chemical Co.). ABTS substrate (Kirkegaard and Perry Laboratories, Inc., Gaithersburg, MD) was added. ELISA plates were read at OD405.
Assays for idiotypic speciJicity. Because human cell lines may secrete varying amounts of immunoglobulin, secreted immunoglobulin from each cloned line was quantitated by ELISA. Goat anti-human immunoglobulin was adsorbed to microtiter wells at 1 Mg/well. Wells were blocked with PBS/3% BSA/5% FCS. Supernatant (100 Ml/well) was added for 60 min at 37°C. Wells were washed with PBS-0.05% Tween, and then incubated for 60 min with either peroxidase linked goat anti-human IgM or peroxidase-linked goat anti-human IgG (Sigma Chemical Co.). ABTS substrate was added. A standard curve was generated with purified IgM and IgG from a normal individual diluted in medium ranging from 0.5 to 50 ug/ml.
Supernatants normalized for immunoglobulin concentration (5 Mg/ ml) by dilution in medium were assayed for idiotypic reactivity. 31 or F4 antiidiotype, which was purified from ascitic fluid, was adsorbed to microtiter wells at 1 or 2 Mg/well, respectively. Wells were blocked with PBS/3% BSA/5% FCS as above and incubated with normalized cell supernatant for 1 h followed by peroxidase labeled goat anti-human IgG, IgM, or IgA (Cappel Laboratories, Cooper Biomedical, Malvern, PA) for 1 h at 1/750 dilution in PBS/1% BSA, followed by incubation with ABTS substrate.
Assayfor DNA reactivity. Anti-double-stranded DNA (dsDNA) activity was determined by filter assay (Millipore/Continental Water Systems, Bedford, MA). DNA was made double-stranded by filtration through nitrocellulose filters. 40 Ml ofa supernatant containing either 5 and/or I Mg/ml of antibody was incubated with 10,000 counts of 32P nick-translated dsDNA for 30 min at 37°C. Samples were then applied to prewet 1" Millipore filter discs (HA 0.45 Mm) and washed through several times under vacuum. Discs were placed in scintillant and counted.
Southern blot analysisfor assaying clonality. Cell lines were assayed for clonality by Southern blot analysis using specific human JK and JH probes (Table I) . High molecular weight DNAs from the EBV lines were prepared essentially as described by Steffen et al. (6) . Briefly, 107 cells were suspended in 5 ml of 100 mM NaCl 10 mM Tris-HCl (pH 7.5) and 1 mM EDTA. The suspension was then mixed with an equal volume of the same buffer containing 1% SDS and 400 Mg/ml proteinase K (Boehringer Mannheim, GmbH, Mannheim, FRG) and incubated for 2 h at 37°C. After incubation, 2 phenol and 2 SEVAG (24:1 chloroform/isoamyl alcohol) extractions, DNA was precipitated with Northern blot analysis of total RNA for V gene utilization. Total RNA was prepared from I X 108 cells using the guanidinium thiocyanate extraction procedure (7). Briefly, frozen or fresh cells were added directly to 4 M guanidinium thiocyanate solution and homogenized immediately using a polytron. This homogenate was carefully layered onto a 5.7 M CsCl cushion and tubes were spun in a SW41 rotor (Beckman Instruments, Inc., Fullerton, CA) at 32 K for 18 h at 20'C. Supernatants were quickly suctioned off. RNA pellets were rinsed in 100% ethanol at 250C, resuspended in 10 mM Tris 1 mM EDTA (pretreated with DEPC), extracted once with Phenol-Sevag solution and precipitated twice with 1/10 volume 4 M NaCl (DEPC) and 2 vol of ethanol. Northern blotting was performed by electrophoretically fractionating the RNA on a 1.2% agarose gel (6% formaldehyde) in 40mM MOPS, 20 mM NaOAc, 2 mM EDTA. The gel was blotted without pretreatment onto nitrocellulose using 20X SSC (3 M NaCl 0.3 M Na-citrate).
Variable region gene families of both heavy and light chains were assigned based upon hybridization of total RNA to each of six probes representing all identified VH gene families and to each of four probes representing all identified VK gene families (Table I) . Plasmids for each VH probe were kindly provided by Jeffrey Berman and Fred Alt of Columbia University. Plasmids containing the K light chain family specific probes were provided by Hans Zachau (University of Munich, FRG). V region specific probes were prepared to insure minimal crosshybridization. Blots were hybridized using nick-translated probes in 50% formamide (EM Science, Cherry Hill, NJ) at 420C overnight. Subsequently, blots were washed in 2X SSC, 0.1% SDS at 680C and autoradiographed.
Sequencing the heavy chain rearrangement ofH2F. 10 gg total RNA was used to reverse transcribe into first-strand cDNA using a specific C-y primer 5'GCCAGGGGGAAGACCGATGG3'. The (Fig. 2) . Analysis ofthe VK families utilized indicates that 31 reactive lines preferentially use a member(s) of the VKI family; all but 2 of 10 31-reactive antibodies are encoded by a VK1 gene (Table III) . No clone expresses more than one VK family. Whereas two lines were derived from the patient with myeloma, neither line is producing the myeloma protein. Both lines produce a VKl-encoded light chain, whereas the myeloma protein is a VK3 encoded light chain (8) .
It is apparent that no single VH region family is used by the 31-positive antibodies (Fig. 3) . Four ofthe six currently defined VH families are expressed in these 31-reactive lines. Even when clones from the same individual are examined, more than one VH family is expressed in 31-reactive antibodies and in the DNA binding subset of 31-reactive antibodies. For example, III-3R, III-2R, and 11-1 are all derived from a single patient; they express a VH3, VHS, and VH1 gene product, respectively. Whereas only three F4-reactive lines were studied, there is no evidence suggesting that a single VH gene family associates with F4 reactivity. Ofthe three F4-positive lines, one uses a member of the VH4 family and two use a member of the VH3 family. Both these gene families are also used in the same patients to encode antibodies that lack F4 reactivity. To see ifF4 idiotypic specificity resides in the third complementarity-determining region, we sequenced the D region ofthe heavy chain from the H2F antibody and compared it to the D sequence of the 2A4 antibody (Fig. 4) IgM antibodies of SLE patients may differ from the IgM antibodies in nonautoimmune individuals.
Discussion
The advent ofhybridoma technology made it possible to generate murine monoclonal antibodies essentially at will. Human hybridoma technology has not been so successful (9, 10) . Fusion frequencies are generally low, stability is poor, and the amount of secreted immunoglobulin is very small. EpsteinBarr virus has also been used to transform human B cells, but EBV-transformed B cells have also been somewhat unstable, when lines are grown as uncloned populations (1 1). Previously, others have reported the generation of only IgM producing B cells (12) (13) (14) . Nakamura et al. generated cloned, IgG-producing lines but only when human peripheral blood mononuclear cells were used as feeder cells (15) . These cloned lymphocytes were stable for only a number of months. In addition, the presence of such feeder cells precludes studies ofcell line RNA and DNA. To study the molecular genetics ofanti-DNA antibodies from patients with SLE, it is necessary to be able to maintain stable cloned IgM-and IgG-producing B cell lines in the absence of any other cells. Therefore, we had to first devise a protocol for generating such lines. In this study the use ofconditioned medium in conjunction with a single round of early cloning by limiting dilution permitted the establishment of long term, stable, clonal EBV-transformed lines. These lines have been growing for over a year and they secrete between 0. We have not yet characterized a sufficient number of F4-reactive antibodies to be certain which VH gene families can encode this idiotype. The limited data available showing that more then one VH gene family can encode F4 reactive heavy chains is consistent with the hypothesis that VH framework residues may not be critical in generating anti-DNA antibodies. In a previous study of myeloma proteins, we found F4 reactivity to be highly associated with DNA binding and almost exclusively associated with IgG antibodies (3). We suggested that the F4 antiidiotype might recognize a somatically generated determinant critical to DNA binding. Sequences of F4-reactive myeloma proteins revealed more than one VH family. A detailed molecular study of one 3I-positive, F4-positive anti-DNA antibody, 2A4, revealed the acquisition of somatic mutations in complementarity-determining regions of the heavy chain (8) . These mutations lead to an accumulation of positive charges and generate the amino acids arginine and asparagine, which have been postulated to be involved in DNA-protein interactions. Similar mutations might occur in a number of different VH germ line genes and generate both F4 reactivity and specificity for DNA. As mentioned previously, there are studies which have shown that antibodies utilizing different VH and VK genes can still express similar idiotopes (17) (18) (19) (20) . Alternatively, the F4 idiotype may be encoded with the VDJ junction and represent a particular D region gene sequence. We do not favor this hypothesis as the D region of the H2F antibody reported in this study differs substantially from that ofthe 2A4 antibody (8) .
The IgG antibodies reported here bind dsDNA as well as the pentameric IgM antibodies despite the fact that IgM antibodies have higher avidity for antigen than their IgG counterparts. Therefore, the IgG antibodies must have higher actual affinity for dsDNA. This result was anticipated because in our studies of myeloma proteins we found DNA binding to be highly associated with IgG isotype in the 31 idiotype system (1). The higher affinity of IgG antibodies found in this study may imply that DNA is a selecting antigen in the anti-DNA response and that affinity maturation occurs for anti-DNA antibodies. Confirmation of this interpretation will be possible once additional lines are available from each patient and the expressed variable region gene sequences and germ line gene sequences are known.
We were somewhat surprised to find that the IgM antibodies produced by the cell lines generated for this study bound dsDNA. The relative avidity of the IgM antibodies reported here for dsDNA is greater than that previously reported for germ line gene-encoded monoclonal IgM anti-DNA antibodies from SLE patients and normal individuals which have been shown by others to bind single-stranded DNA (ssDNA) but have little or no ability to bind dsDNA (10, 12, 13, 16) . Binding to ssDNA is generally believed to be a property of nonpathogenic antibodies. Previous studies on myeloma proteins had suggested that 31-reactive IgM antibodies infrequently bind DNA. That IgM producing 31-reactive lines derived from SLE patients bind DNA is, however, consistent with the observation that IgM anti-DNA antibodies are not uncommonly present in the serum of SLE patients (22) . There are several possible interpretations for this observation. The SLE-derived 31-reactive IgM antibodies may preferentially use a subset of antibody genes that in their germ line configuration encode 31-reactive dsDNA binding antibodies. It is also possible that SLE patients possess polymorphisms of immunoglobulin genes that lead to anti-DNA reactivity of germ line-encoded antibody molecules. Alternatively, IgM antibodies from SLE patients may be more likely to be mutated than those produced by malignant B cells; hypermutation may be a feature of SLE. Somatic mutation may occur earlier in B cell ontogeny or at higher frequency. Finally, EBV transformation may be selective for those B cells that are activated and thus are more likely to have acquired mutations so that sampling an EBV-transformed B cell repertoire will yield different data than sampling a malignant B cell repertoire. The monoclonal proteins that express an autoantibody-associated idiotype but were derived from patients with monoclonal gammopathies may not faithfully mirror the idiotypically-related antibodies in autoimmune disease and reinforces the importance of technologies for directly studying the autoantibodies produced by nonmalignant B cells.
